Referral pathways may include endocrinology, diabetes self-management education and support (DSMES), registered dietitians, and bariatric medicine specialists as appropriate for complex cases or when treatment goals are not met with standard approaches
Retatrutide is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors currently being studied as an investigational medicine for obesity and type 2 diabetes (phase 2 data published in the New England Journal of Medicine, 2023)
Those most at risk include vegans and vegetarians, people with digestive conditions such as Crohn's disease, coeliac disease or IBS, those taking long-term metformin or proton pump inhibitors, older adults whose ability to absorb B12 through the gut declines naturally with age, those with pernicious anaemia, and anyone with a history of chronic alcohol use
you are following a plan designed by experts to help you reach your goals safely and effectively
Nausea may return briefly after each dose increase